| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal crohn’s disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Grace Gathungu, Yuanhao Zhang, Xinyu Tian, Erin Bonkowski, Leahana Rowehl, Julia Krumsiek, Billy Nix, Claudia Chalk, Bruce C Trapnell, Wei Zhu, Rodney D Newberry, Lee A Denson and Ellen Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Institutes of Health |
R01 DK098231 |
| National Institutes of Health |
R01 DK078683 |
| National Institutes of Health |
P30DK052574 |
|
| Corresponding Author |
Grace Gathungu, MD, Assistant Professor, Department of Pediatrics, Division of Pediatric Gastroenterology, Stony Brook University Medical Center, HSC T11-080, Stony Brook, NY 11794-8111, United States. grace.gathungu@stonybrookmedicine.edu |
| Key Words |
Inflammatory bowel disease; granulocyte-macrophage colony-stimulating factor antibody; Crohn’s disease; surgery |
| Core Tip |
This retrospective study assesses the risk of surgery for management of ileal Crohn’s disease (CD) among patients with elevated granulocyte-macrophage colony-stimulating factor (GM-CSF) auto-antibodies (Ab). In this cohort, 396 subjects underwent initial ileocecal resection or ileal resection for management of disease. Subsequently 165 patients (41.7%) required a second ICR or IR. Factors predicting faster time to a second surgery were elevated GM-CSF Ab and elevated GM-CSF cytokine. Patients with low GM-CSF cytokine levels and the protective allele for ATG16L1 had longer intervals between a first and second surgery. To improve long term outcomes for patients with Ileal CD we need to optimize therapeutic options for patients with low GM-CSF bioavailability and genetic risk markers for ATG16L1. |
| Publish Date |
2018-01-31 01:17 |
| Citation |
Gathungu G, Zhang Y, Tian X, Bonkowski E, Rowehl L, Krumsiek J, Nix B, Chalk C, Trapnell B, Zhu W, Newberry R, Denson L, Li E. Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohn’s disease. World J Gastroenterol 2018; 24(5): 623-630 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i5/623.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i5.623 |
